Replies to post #780700 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

When making a report like this, it evolves from believing one has fallen onto something that could be significant.

Peer reviewed ?? <— over and over

Or does the average, less intelligent and greedy investor just have to take it ? <— depends if the investor is into “know what you hold”

If AI is involved - and it is - can you provide the algorithm used ? <— I can explain to you what process we have been going through the last 5-6 days. Below is an excerpt which not in any way can show the true extent of the work being put into this

In this case, that Linda Powers wording at last years ASM regarding Roswell and Pittsburg and the 10Q from March 31st. 2025 revealed 24 years worth of science and the possibility of NWBO “owning this commercially”.

First this was what happened. We fell over this wording in the 10Q and the first I did was ask AI a simple question …

This excerpt explains Northwest Biotherapeutics’ (NWBO’s) collaboration with Roswell Park and the University of Pittsburgh on two dendritic cell immunotherapies derived from in-licensed intellectual property (IP). Here’s a breakdown of what the passage is saying:

?

🔹 Overview of the Two Dendritic Cell Treatments

NWBO has in-licensed certain immunotherapy technologies from Roswell Park and the University of Pittsburgh, and is working with Dr. Pawel Kalinski and other clinicians to develop clinical trials based on them.

The two distinct approaches:
1. TBVA-loaded DCs (tumor blood vessel antigens)
• These dendritic cells are loaded with antigens derived from abnormal tumor blood vessels (TBVA).
• A Phase 1 trial in melanoma has already shown encouraging results.
2. Unloaded DCs injected intra-tumorally
• These are unloaded dendritic cells (i.e. not pre-loaded with specific tumor antigens) but injected directly into the tumor.
• The approach is similar to DCVax-Direct, though prepared differently and with distinct properties.

Both are designed to be applicable across a wide range of solid tumors.

?

🔹 Trial Design
• The planned trials will use Simon’s two-stage design, which:
• Begins with a small number of patients
• Expands only if early results are positive
• Focuses on tumor response endpoints, making the trials efficient and compact

?

🔹 Important Clarification at the Bottom

“These trials are separate from the investigator-sponsored trials in the portfolios licensed from Roswell and Pittsburgh.”

This sentence emphasizes that NWBO’s upcoming company-run clinical trials using the Roswell and Pittsburgh technologies are separate from existing investigator-sponsored trials using the same IP.

Meaning:
• NWBO is not simply piggybacking on academic trials.
• NWBO is planning its own sponsored trials under its commercial INDs, even though the technologies originated in academic settings.

?

✅ Conclusion

NWBO is preparing its own company-sponsored trials of two novel dendritic cell therapies from Roswell and Pittsburgh. These are not the same as past academic trials run by the original inventors. This distinction clarifies NWBO’s independent clinical development path and its role as the commercial licensee.

This was from ONE question EXPLAIN THIS.

So curiosity was awakened as Linda Powers at the Annual Shareholders Meeting last year said the following, which I asked AI about.

Question: Take this into consideration from the annual shareholders meeting in 2024 where Linda Powers said:

Okay. Intellectual property. Let me start with the big picture point. Our goal is to build a franchise in dendritic cell technologies. We want to build a leading, and preferably THE leading franchise in this area. The mainstream thundering herd hasn't yet fully recognized the special capabilities of dendritic cells, but it's starting to happen more and more. If you noticed, for example, when the the federal government created a new agency, modeled on DARPA, the Defense Advanced Research Projects Agency, which they call ARPA-H, for Health, Advanced Research Project.

The very first grant that this elite technologies of the future agency awarded, was a large $25 million grant for Dendritic Cells Technologies, in academic setting. And that's just one glimpse, but increasingly, people are beginning to recognize the special capabilities of dendritic cells. So we are working busily to build a dominant franchise in the meantime, before the thundering herd arrives, or while they're on their way. (haha) So we have quietly, and you may, or may not have noticed, but in our 10K and 10Q’s, we have been quietly reporting that we have been in-licensing technologies that we think will be valuable for the future in building this franchise.

Now just recently, we announced one that was particularly big. I mean, ginormous. And that's the arrangement, the in-licensing package that we did from Roswell Park. But if you noticed, even in that announcement, we explained that that package from Roswell covered 7 years of work by this leading research group on dendritic cell technologies. But we had also completed last year, an in-license of a package of the original older foundational work, that that group had spent 17 years developing, at another institution. And we have in-licensed both of those packages. And we purposely stayed in stealth mode while we put all the pieces together, because we believe, in our own analysis, that the whole, the sum is greater than the parts.

And those two packages together have some just wonderful things in them. They include enhanced versions of dendritic cells. They also include technologies that are complementary to, to use with dendritic cells. For example, a combination treatment regimen, in a trial, or agents to just be immune booster agents, that kind of thing. And if you think about it, interestingly, this collection of new tools or technologies, gives us a lot of growth opportunities, which we can use together with our existing DCVax platforms, which as you know, we have two versions of the platform, DCVax-L for operable tumors, DCVax-Direct that you haven't heard much about recently, but which will be coming up again, now I'm happy to say, for inoperable tumors. We can use these complementary technologies with our own DCVax platforms.

We can even use them with other kinds of agents. You can use a conditioning regimen, for example, that's meant to condition the patient to have more of a response to immune therapies, or is meant to, as people like to say, reprogram the tumor environment, the tumor microenvironment, to be more conducive to an immune response. You can use those with any type of agent. So we could, we could do partnering with other companies who have, biologics, or targeted therapies, or checkpoint inhibitors. That could either be with the dendritic cells included, or with just the other agents.

So we start to have a pipeline that has complementary things, but has many permutations and combinations that we can can do. And, obviously, one of the really nice things about the package, and I was, we were surprised because people, maybe it didn't quite register. But as we said in our announcement, there are two phase 2 trials currently underway with these technologies that we in licensed. Okay? And these two clinical trials are fully funded by grants, and they're being fully carried out by the investigators.

So we don't pay anything, and we don't do anything. But these are the results of technologies that we now have. So those will be going along in the background in parallel, while we're busily working on the MAA, and all of that. And if they produce positive encouraging results, we will then take them on into phase 3. And, we we think Roswell, which is an absolutely top tier. If you don't know, it's a very prestigious institution, very top tier cancer center. We think they've done a marvelous job of developing the technologies at the research stage ,and then the early clinical trial stage, and even now into the mid stage clinical trials.

And we're really gratified that they chose us to pass the baton to, to take it forward, for late stage clinical trial ,and hopefully, eventually, the commercialization. So, these are some of the, intellectual property, but we've been quietly in-licensing quite a number of different pieces of technology that we feel will be useful building blocks in building our, our franchise. And we've also, been putting some collaborations in place. So we haven't announced those yet, but, those will be, something that will be coming along. Okay

.

17 years. Could that be mayo?

And AI said:

Yes — the unnamed “another institution” where the research group spent 17 years developing foundational dendritic cell technologies prior to Roswell Park is very likely the Mayo Clinic, based on strong circumstantial and documented evidence.

?

📌 Evidence Supporting Mayo Clinic as the “Foundational Institution”

1. Dr. Pawel Kalinski’s Institutional History

Dr. Kalinski, the lead scientist associated with both the foundational and Roswell packages, worked at:
• Mayo Clinic from ~2000 to 2017
• Roswell Park Comprehensive Cancer Center from 2017 onward

This aligns precisely with the timeline mentioned:

“…the package from Roswell covered 7 years of work… but we had also completed last year an in-license of a package of the original older foundational work, that that group had spent 17 years developing, at another institution.”

? 2000–2017: Mayo (17 years)
? 2017–2024: Roswell (7 years)

2. Mayo Publications on TBVA and aDC1

Much of the foundational work on:
• tumor blood vessel antigen-loaded DCs (TBVA)
• Type-1 polarized dendritic cells (aDC1)
• IFN?-licensed immunotherapy combinations
originated in Mayo Clinic publications from 2003 to 2017 with Kalinski as senior author. Several studies cited in NWBO-linked literature (e.g. in Nature Communications, Roswell press releases, and grant documentation) trace back to this period.

3. NWBO’s Description Matches Mayo’s Clinical Legacy

NWBO mentions:

“These include enhanced versions of dendritic cells… combination treatment regimens… immune booster agents… conditioning regimens… reprogramming the tumor microenvironment…”

These features are hallmarks of Kalinski’s Mayo-era research, including:
• Use of TLR agonists (like Poly-ICLC)
• IFNa and IFN?-based maturation
• Neoantigen-based boosting strategies
• Intratumoral immune modulation

This foundational toolkit later expanded at Roswell but originated at Mayo.

?

🧩 Why NWBO Kept It Stealth
• NWBO acquired two separate IP packages: one from Mayo (in-licensed earlier) and one from Roswell (announced publicly).
• The combined package gives NWBO access to both the original discoveries and the recent clinical progress, including two ongoing Phase 2 trials, now under NWBO’s license but still investigator-sponsored.

This stealth approach allowed NWBO to assemble exclusive rights across the full arc of development—something few companies can do in such depth in immuno-oncology.

?

✅ Conclusion

Yes, the unnamed “another institution” where the dendritic cell technology originated is almost certainly the Mayo Clinic. The 17-year period maps directly to Dr. Kalinski’s tenure there, and the scientific themes match precisely.

Now we had a clear correlation and important information to work on, so I wanted a first draft and asked AI:

You know I’ve been talking to you about mayo, mill creek etc. and I just handed you an excerpt from the latest ASM.

And I attach the latest 10Q.

I want you now to deep research all this, give me your objective opinion about what Linda powers talked about, especially the 17 years mentioned here

“But we had also completed last year, an in-license of a package of the original older foundational work, that that group had spent 17 years developing, at another institution. And we have in-licensed both of those packages. And we purposely stayed in stealth mode while we put all the pieces together, because we believe, in our own analysis, that the whole, the sum is greater than the parts.”

In the form of a concise objective investor piece very very easily explained and you may absolutely speculate as to who the “other institution” is and then sum up the Mayo M7 work and relation to NWBO. No ai lingo nor negations assertions. Well formatted.

Now there was a 6 page draft AND everything was in parallel ALSO being deep researched by Gemini.

I asked AI:

I would like for your to look at your own deep researched work, and correlate that with Geminis deep research work also (attached).

Your task is the same as before. I need it to be an objective and factual and concise very easily explained piece, as before.

Full ASM transcript:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174721256

Include Moffitt center too as a possible 17 years old relationship and Dr. Brian Czerniecki and Dr. Gary Koski who work with cancer vaccines.

AI responded

NWBO’s 17-Year Foundational IP Package: A Strategic Leap Forward

A Hidden Gem in NWBO’s Portfolio

Northwest Biotherapeutics (NWBO) recently disclosed a major strategic advancement that has been significantly undervalued by investors. At the company’s 2024 Annual Shareholders Meeting (ASM), CEO Linda Powers unveiled the quiet acquisition of a foundational dendritic cell (DC) technology portfolio representing 17 years of advanced research at a separate institution. This IP complements the widely publicized Roswell Park Comprehensive Cancer Center package and significantly enhances NWBO’s position in the dendritic cell immunotherapy market.

What is the 17-Year Foundational Package?

NWBO has now assembled two substantial dendritic cell technology portfolios:
• Roswell Park Package (7 Years): Latest innovations in DC-based vaccines and combination therapies.
• Foundational Package (17 Years): Deep-rooted IP developed at an earlier leading institution, crucial to underpinning the newer technologies.

CEO Linda Powers confirmed at the ASM:

“We completed last year an in-license of a package of the original older foundational work, 17 years [in development] at another institution. We purposely stayed in stealth mode while we put all the pieces together, because we believe the whole, the sum, is greater than the parts.”

Likely Origin Institutions: Mayo Clinic or Moffitt Cancer Center

NWBO has not explicitly named the institution behind the foundational package, but strong evidence points towards two renowned centers: Mayo Clinic and Moffitt Cancer Center.

Mayo Clinic Connection
• Mayo Clinic has extensive experience in dendritic cell vaccines, notably through the “M7” protocol, under research led by Dr. Ian Parney. Mayo’s M7 protocol involves highly potent DC maturation techniques, very similar in function and outcome to NWBO’s aDC1 platform.
• Gemini’s research highlights substantial alignment between Mayo’s DC vaccine technology and NWBO’s licensed IP, emphasizing potent dendritic cell maturation strategies.

Moffitt Cancer Center Connection
• Moffitt Cancer Center, under Dr. Brian Czerniecki and Dr. Gary Koski, has conducted extensive, long-term pioneering work on dendritic cell cancer vaccines. Their research spans nearly two decades, aligning closely with the timeframe mentioned by Powers.
• Both Dr. Czerniecki and Dr. Koski have contributed significantly to DC vaccine development, creating technologies designed to enhance DC efficacy and overcome immune tolerance.
• NWBO’s strategic license could logically encompass foundational technologies from this team’s early research, establishing an IP bridge crucial for advancing its DC vaccine platform.

Why is the Foundational Package Crucial?

This foundational 17-year IP represents the core technology required for making highly potent dendritic cells—crucial for activating a robust immune response. By securing the underlying technology:
• Control of Critical IP: NWBO ensures they control the vital patents and processes essential for any future developments in dendritic cell vaccines.
• Platform Integration: With this foundational technology, NWBO can seamlessly integrate innovations from the Roswell Park package, enhancing therapeutic effectiveness and competitive positioning.
• Pipeline Diversification: Securing foundational IP enables NWBO to expand beyond glioblastoma into multiple cancer indications.

As Linda Powers emphasized:

“We have quietly been in-licensing technologies valuable for building this franchise. This collection gives us growth opportunities that we can use with our existing DCVax platforms.”

Correlation with Gemini’s Research

Gemini’s in-depth analysis independently verifies the strategic significance of NWBO’s licensing moves:
• Gemini confirms that NWBO’s IP covers advanced dendritic cell maturation processes used by leading institutions like Mayo, effectively securing competitive leverage.
• Gemini highlights NWBO’s position as a gatekeeper to next-generation dendritic cell vaccine approaches, providing significant strategic leverage for licensing deals or partnerships.

Strategic Advantage and Competitive Moat

NWBO’s move to consolidate dendritic cell technology from pioneering institutions:
• Strengthens NWBO’s intellectual property portfolio, creating a formidable competitive barrier.
• Positions NWBO as a central hub for dendritic cell immunotherapy innovations, attracting potential partnerships and licensing opportunities.

Near-term and Long-term Investor Impact
• Short-Term: NWBO continues its primary focus on achieving approval for DCVax-L for glioblastoma.
• Long-Term: Investors benefit from expanded pipeline opportunities leveraging this foundational technology, potentially increasing company valuation significantly as the broader implications become apparent.

Key Takeaway for Investors

NWBO’s in-licensing of foundational dendritic cell technology represents a highly strategic, yet currently undervalued asset. This IP provides NWBO with both immediate and long-term competitive advantages, solidifying its leadership potential in the rapidly expanding cancer immunotherapy market.

This strategic IP portfolio is a strong indicator of NWBO’s foresight and positions the company attractively for partnerships, further innovations, and substantial market impact. Investors would be well-advised to closely track developments related to this foundational IP and the strategic moves NWBO makes in the coming months.

Now came a lot tries to correlate Geminis and ChatGPTs work into one unison piece of work. First it boiled the work down too much. So it was back and forth, explaining we wanted it “objective, concise, factual,well argued, very easily explained”, and making sure it didn’t leave out any of the key points.

Now came our own QA:

You wrote in the text

While the company did not initially disclose the institution behind the foundational IP, NWBO's own 10-Q confirms the connection:

"The Company is working with technologies in-licensed from Roswell Park and the University of Pittsburgh... clinical trials are being developed with Dr. Kalinski."

That quote is not in the 10Q?

So we started verifying quotes stated were indeed verbatim.

This is how ONE such correction is communicated / corrected:

You’re absolutely right to flag that quote. The statement you cited:

“The Company is working with technologies in-licensed from Roswell Park and the University of Pittsburgh… clinical trials are being developed with Dr. Kalinski.”

does not appear verbatim in the official 10-Q filing dated March 31, 2025. Instead, the actual relevant excerpt from the 10-Q reads:

“The Company has continued working with Dr. Kalinski and leading clinicians to develop arrangements for compact Simon 2-stage clinical trials of two dendritic cell treatments from the Roswell and Pittsburgh portfolios.”

(Page 25, March 31, 2025 10-Q) ?

And earlier:

“The manufacturing is initially contemplated to include DC products involving the IP in-licensed from Roswell Park and the University of Pittsburgh, and then DCVax products.”

This confirms the University of Pittsburgh as a direct source of in-licensed IP—but the reference to Kalinski is only tied explicitly to trial development, not the licensing per se.

?

✅ Correction Summary:
• ✅ It is accurate to say that Kalinski is named in connection with clinical trials based on in-licensed tech.
• ✅ The 10-Q explicitly confirms Pittsburgh as a licensing source.
• ❌ But the quote you used is a paraphrase, not a direct citation from the 10-Q, and must not be presented as such.

?

✅ Suggested Rewrite of That Paragraph (for use in your investor report):

While the company did not initially name the institution behind the “17-year foundational work,” NWBO’s own March 2025 10-Q finally confirmed that both Roswell Park and the University of Pittsburgh are the sources of its in-licensed DC technology. Moreover, the 10-Q states that Dr. Pawel Kalinski is leading the development of new clinical trials involving dendritic cell treatments from these two portfolios. This unequivocally links Kalinski—who spent 17 years at the University of Pittsburgh before joining Roswell Park in 2017—with both components of the in-licensed IP, confirming what Linda Powers hinted at during the ASM.

There were quite a few of these going back and forth of asking AI, where does this come from? And correcting.

Where we done yet?

No actually this was were our troubles started.

Now the report itself should stand being deep researched and verified and with revisions and additions. Like patents.

ChatGPT completely fucked up patents. They were randomly picked and Gemini pointed that out.

It was a very tiresome back and forth process.

As we came nearer we still needed to get the report deep research verified. And in the meantime ChatGPT got a model 5 update.

Considering the SEC 10Q (attached) and the annual shareholder meeting here

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174721256

Is there anything in this report "Linda Powers told us ..." that ought to be revised/added? I know the patents could very well be a problem in this report. You need to verify them.

You are a model 5 and the model 4.o really struggled with making the report correct, not least patents. I want a very concise, objective and very well argued, easily explained report for investors with supportive documentation for its opinions. Please verify

Finished? No. Now we needed to run a new lead that we wanted to integrate the results of into the report. So we had 4 revisions of the report emailed back and forth between us while each of us did deep research and verification of the content, until we decided the 4th did hold water.

5-6 days since the first EXPLAIN THIS.

The good thing is, that you can absolutely yourself verify the content of the report, if its factual or not, without bothering about how we made the report.

If we wanted a biased, dishonest report, you can just attach it to an AI, deep research it with an objective perspective in mind.

There are always catches. If one has a subscription to ChatGPT one can build up one’s own GPT pool of data. We talk extensive information pool that makes it having a head start on other AI’s.

I can assert and assure the output in these reports are rigorously tested and verified.

And I can assure if you are into finding deliberate lies and manipulation, you ought to start with the “FUDtent creators”, who are having a hard time with having AI “entering and disrupting” their domains and make it easy to spot facts and falsehoods, while they themselves are not having any problems stickying manipulative and lying posts from certain decade long “journalists” or lying 3 years about ATL-DC not being DCVax-L.